Does switching from oral extended-release methylphenidate to the methylphenidate transdermal system affect health-related quality-of-life and medication satisfaction for children with attention-deficit/hyperactivity disorder?

Table 3 Caregiver MTS treatment satisfaction at endpoint, ITT population

MSS Summary	Agreement, %^a N = 161
Satisfied with frequency of daily dosing	97.5
Satisfied with ease of use	96.2
Child rarely missing a dose	97.5
Satisfied with child's behavior	93.8
Improvement in child's social interactions	82.6
Satisfied with how child pays attention	91.9
Satisfied with duration of effect on symptoms	93.1
Overall satisfaction	93.8

^a"Strongly agree", "agree", and "somewhat agree" were combined into the "agreed" category.
MTS = methylphenidate transdermal system; ITT = intent to treat, MSS = Medication Satisfaction Survey.

ISSN: 1753-2000